- Select a blog category
The term ‘revolution’ is often used to define a popular uprising that can lead to dramatic political changes. A dictator is overthrown, a new government is formed, a constitution is changed or replaced, and immeasurable impact on the country or even the world can occur. However, other types of revolutions also happen. Some of the most commonly known are industrial revolutions, which refer to breakthroughs in technology that change how industries function. We are now seeing the beginnings of a fourth industrial revolution – a fusing of technologies blurring the boundaries between the physical, digital and biological worlds.1 This blog highlights the issues that Deloitte believe will cause the most disruption for life sciences in 2018 as we embark on this fourth industrial revolution.
Most people will have been impacted by cancer in some way – whether themselves, a family member, a loved one or an acquaintance. Stories about the causes of cancer and examples of exciting new breakthrough treatments feature regularly in media headlines. However, one issue more than any others attracts attention, and that’s evidence of inequalities in patient outcomes. Last week’s World Cancer Day, on 4th February, coincided with the publication of the CONCORD-3 report, comparing the outcomes for cancer patients from 73 different countries over the period 2000-2014.1 This week’s blog reflects on some of the developments in the UK given the results of this ground breaking research suggests that the UK continues to lag behind many other comparable European countries.
In November 2017 we published our report Time to care: Securing a future for the hospital workforce in Europe. The research for the report examined how hospitals in 14 countries across Europe are responding to the challenge of clinical workforce shortages in the face of growing demands from people with more complex health care needs. It identified universal concern about workforce shortages and the lack of time for hands-on care. Last week, Deloitte Ireland published it’s Time to care report supplement, based on its analysis of our research evidence on the Irish healthcare system, particularly the findings from the Irish cohort of our crowdsourced survey.
As discussed in our report The future awakens: Life Sciences and Health Care Predictions 2022, incorporating technologies into our health care systems is crucially important if we are to improve both the patient journey and the efficiency and effectiveness of our health care services. This week’s blog is by Terri Cooper, Deloitte’s Global Health Care Sector Leader and first featured as a US Centre blog in November 2017.1 Her blog examines the ways technology can improve the delivery of health care, and reviews some of the key use cases developed by 33 participants in a crowdsourced simulation exercise facilitated by the US Center for Health Solutions.
In December, we published our eighth annual report on Measuring the return from pharmaceutical innovation. This series of reports tracks the annual return on investment (ROI) that 12 leading biopharma companies (by 2009 R&D spend) are projected to achieve from their late-stage pipelines. For the third consecutive year, we also tracked the performance of an extension cohort of four mid-to-large cap biopharma companies in order to compare their performance with our original cohort. This week’s blog briefly summarises the performance of our two cohorts and then explores some emerging technologies that we anticipate should increase the productivity and efficiency by which drugs are discovered, developed and brought to patients.
This week Deloitte launched its report, 2018 Global health care outlook: The evolution of smart health care - which looks at the challenges health care will be facing in 2018 and the strategies that can be utilised to alleviate the pressures facing the sector globally. This week’s blog highlights some of the key findings from the report and their implications for the UK.
This week, we published our eighth annual report on Measuring the return from pharmaceutical innovation. Our report tracks the annual return on investment that the 12 leading biopharma companies (by 2009 R&D spend) might expect to achieve from their late-stage pipelines, as well as tracking the performance of an extension cohort of four mid-to-large cap biopharma companies for the third consecutive year. This week's blog by Matthew Thaxter, an analyst at the centre, gives his take on the findings from this year’s report.
Stories give people permission to talk – they give staff, patients and their families a voice that touches everyone who listens. Last week we published our report Time to care which highlights the importance of supporting the physical and mental wellbeing of hospital staff in order to ensure a sustainable and effective workforce. This Thursday I attended an inspiring event called ‘The DNA of Care’, a shared learning event hosted by NHS England. The event showcased a series of digital stories developed by Patient Voices and an evaluation of how digital stories are being used to provide a voice to NHS staff as part of their DNA of Care project.1 During the event I was struck by the power of staff stories and how these stories could help tackle some of the challenges identified in our research. I have long been a strong advocate of the power of digital stories. This week’s blog shares some of my insights from this event and why I believe digital stories are not only incredibly impactful and cathartic for the people involved in telling their stories, but can help others understand the amazing courage, resilience and compassion of NHS staff.
Access to high-quality health care is a fundamental human right, for improving the health of both individuals and the population as a whole. Health professionals are the most important asset in any health system and represent a significant investment. While countries differ in how they fund health care, how much they are prepared to pay for services and which services they prioritise, the quality of care is dependent on having the right professionals with the right skills in the right place at the right time. This week we launched our latest report, Time to care: Securing a future for the hospital workforce in Europe. The overarching theme is a universal concern about workforce shortages and the lack of time for hands-on care. Countries across Europe are facing increasing challenges with regard to the growing demands placed on the workforce which raises important questions about the sustainability of current workforce models. Having led the research for this report for the past six months, this week’s blog provides my take on the report’s key findings, the challenges identified and some of the potential solutions to these challenges.
This month we published our report The future awakens: Life sciences and health care predictions 2022, where we discussed the future of medicine and how technologies such as genomics, precision therapies and artificial intelligence (AI) will shape our understanding of our own genetic make-up and ultimately improve patient outcomes. One technology that we didn’t highlight in the report, is nanotechnology, principally because we expect it to take more than five years to become a central part of healthcare. Nanotechnology has been touted as a technology that could revolutionise our world since the late 1950’s. However, scientific and economic barriers means the commercialisation of products incorporating nanotechnology in life sciences has been limited. Despite this lack of commercialisation, a new wave of nanotech-based therapies are on the horizon. This week’s blog by Amen Sanghera, an analyst here at the Centre who studied the topic at university, looks at the potential benefits and current limitations of nanotechnology in the life sciences industry.
In 2014 we launched our first predictions report - Healthcare and life sciences predictions 2020: A bold future? It provided an intentionally positive and provocative view of what the world might look like in 2020. Since then the pace and scale of innovation has meant that some of these predictions are already a reality, while some are still some way off; yet others may never happen. Moreover, in the intervening years, the life sciences and health care industries are waking up to the fact that new science, automation and robotics will have a significant impact on the future of work. Last week we launched our newest predictions report - ‘The future awakens: Life Sciences and health care predictions 2022’. This week’s blog provides an overview of our six predictions and an example of the evidence today that enables us to say with some confidence what tomorrow might look like.